Scale-ups already growing strongly may not consider a public listing as necessary, or may find themselves daunted by the process or put off by the prospect of enhanced scrutiny of their business. ...
Scale-ups already growing strongly may not consider a public listing as necessary, or may find themselves daunted by the process or put off by the prospect of enhanced scrutiny of their business. ...
Natixis recently led a 180m convertible bond issue for GENFIT, which develops therapeutic solutions in metabolic and inflammatory diseases that notably affect the liver. This issue is the largest ...